Page 2,004«..10 20..2,0032,0042,005 2,006..2,010 2,020..»

Category Archives: Transhuman News

Does Valeant have the ad dollars to keep Siliq competitive in psoriasis? – FiercePharma

Posted: March 4, 2017 at 12:48 am

Yes, Valeant has a safety warning weighing down new psoriasis med Siliq as it prepares to enter the market. But its got another issue, too: the fact that its going up against some major spenders in the field.

When it launches, Siliq will take on fellow IL-17 meds Cosentyx from Novartis and Taltz from Eli Lilly, but it will also have to contend with the anti-TNF giantsAbbVies Humira included. As Wells Fargo analyst David Maris pointed out last month in a note to clients, the Illinois pharma spent $357 million on Humira advertising in 2015 alone.

It also regularly tops pharmas TV ad spending list, shelling out $35 million in January, according to tracker iSpot.tv.

That could be a problem for a company in financial straits as dire as Valeants; the debt-laden company has been plagued by default concerns since last year, thanks to years of debt-fueled M&A dealmaking under former skipper J. Michael Pearson.

And while the company plans to keep itsSG&A spending in 2017 between $2.6 billion and $2.7 billion, its got some other key priorities this year, too: Its planning to relaunch flopped female libido drug Addyi, and its expanding its primary care sales force for lead med Xifaxan in the wake of canceled GI unit deal talks with Japans Takeda.

The financial concerns add to the safety burden Valeant is already facing with its psoriasis newcomer. The med comes along with a black-box warning on suicide risks and a substantial risk-managing program, under which physicians and pharmacies will have to be certified toprescribe and dispensethe med and patients will have to signinformed consent agreements before taking it.

All things considered, we believeSiliqis a sub-competitive drug in a competitive market that Valeant cannot afford to compete in, Maris wrote following the products February FDA approval.

Valeants management, though, thinks Siliq can stand out from the crowd based on its clinical benefits. As CEO Joseph Papa told investors on the companys Q4 conference call, Siliqunlike its IL-17 peersis a receptor-blocker, and when you can actually block the receptor, you tend to get a better, a quicker response and also a response that is more durable.

And some analysts agree. Siliqoffers differentiation on efficacy parameters relative to competitors, Barclays Doug Tsao wrote to clients, noting that though Valeant is splitting profits down the middle with developer AstraZeneca, the 90% profit margins and relatively concentrated prescriber base makeSiliqan attractive opportunity even if Valeant can get 5% to 10% market share.

Read the original:
Does Valeant have the ad dollars to keep Siliq competitive in psoriasis? - FiercePharma

Posted in Psoriasis | Comments Off

J&J may be late to the psoriasis drug market party, but it’s planning to make a splash with guselkumab – Endpoints News

Posted: at 12:48 am

J&J has reaped the final harvest of Phase III data it is taking to regulators in search of a blockbuster approval for their psoriasis contender guselkumab.

J&J is widely expected to use this latest batch of reliably positive data to clean up on major approvals at the FDA and EMA. But its favorable late-stage comparisons with Humira may not count for so much these days, as the pharma giant is bringing up the rear of a parade of new drugs that got to the market first.

Novartis Cosentyx got out ahead 18 months ago and the Swiss pharma giant has followed with 4-year data tracking a solid success 43.5% in keeping skin cleared over the long haul. Eli Lilly backed its new drug Taltz in a major campaign last fall. And then Valeant ambled across the finish line with brodalumab now dubbed Siliq two weeks ago. Their drug, picked up at a discount from a disappointed AstraZeneca, also comes with a black box warning on suicidal thinking that will almost certainly squeeze its slice of the market down to a sliver.

Now comes J&J, a global powerhouse, with a contender it believes is already positioned for success.

As we saw in the first Phase III, VOYAGE 1, guselkumab handily outscored a placebo on two measures of complete or near-complete skin clearance in VOYAGE 2. And once again their IL-23 drug slapped aside Humira, with guselkumab versus adalimumab achieving an IGA 0/1 score of 84% versus 67.7% and a PASI 90 of 70% compared to 46.8%, respectively.

The results were remarkably similar, which is what you want to see, Philippe Szapary, VP for dermatology and gastroenterology in J&Js Immunology Clinical Development unit, tells me about his Phase III studies.Its very reassuring to see such amazing consistency.

J&Js third Phase III study looking at patients transferred to guselkumab after an inadequate response to their other psoriasis drug Stelara also looked good. The statement notes:

Patients who switched to guselkumab consistently showed greater improvement in their psoriasis between weeks 28 and 40, compared with patients who continued to receive Stelara, having twice as many office visits with at least a 2 point improvement in IGA from week 16, the studys primary endpoint, and an IGA score of 0 or 1.

J&J gained a new approval for Stelara last fall, adding Crohns to the label as the company looked to keep its performance in blockbuster territory. The new Navigate study also positions J&J to keep about 30% of psoriasis patients who dont respond well to Stelara in the fold, so to speak.

Investigators also reaped a satisfying profile on safety, with a somewhat better set of data on adverse effects compared to Humira, which remains a big player in this field as AbbVie continues to fight off biosimilar competition. There is also one more psoriasis drug waiting in the wings. Sun Pharma gained control of Mercks MK-3222, but it isnt expected to hit the market anytime soon.

The next step is to keep gathering data with extension studies that will take the 1800 patients enrolled for VOYAGE 1 and 2 out about five years. With a target lying upstream of IL-17 and TNF, he adds, investigators are hopeful that guselkumab will continue to perform well against competition long after it arrives on the market.

Go here to see the original:
J&J may be late to the psoriasis drug market party, but it's planning to make a splash with guselkumab - Endpoints News

Posted in Psoriasis | Comments Off

National Psoriasis Foundation 2016 Medical Professional Awards Winners – PR Newswire (press release)

Posted: at 12:48 am

Outstanding Educator in Psoriatic Disease, Joel M. Gelfand, M.D., MSCE.Joel M. Gelfand is Professor of Dermatology and of Epidemiology at the University of Pennsylvania. He is a board-certified dermatologist whose clinical work focuses on general dermatology and psoriasis. He has created a multi-disciplinary approach to the care of psoriasis patients at Penn through his recruitment and mentoring of a rheumatologist and cardiologist who now specialize in systemic complications of psoriasis.

Outstanding Physician-Clinician, Alexa Boer Kimball, M.D., M.P.H Alexa Boer Kimball, M.D., M.P.H. is the president and chief executive officer of Harvard Medical Faculty Physicians, an academic multi-specialty group employing more than 1,200 full-time Harvard Medical School faculty members and 450 physicians in the community. She is also President of the Beth Israel Deaconess Care Organization Physician LLC, which maintains a membership of approximately 2500 physicians, and a Professor of Dermatology at Harvard Medical School.

Dr. Kimball is an international expert on psoriasis and hidradenitis suppurativa who has published more than 250 peer-reviewed scientific papers and 100 Questions and Answers about Psoriasis, which has been translated into Spanish, Greek and Korean. In 2016 she was named Mentor of the Year by the Women's Dermatologic Society.

Health Professional Volunteer of the Year Craig F. Teller, MDCraig F. Teller, MD, is a native Houstonian and has been practicing dermatology since 1995. Board certified by the American Board of Dermatology and a fellow of the American Academy of Dermatology, Dr. Teller holds an academic appointment as Clinical Instructor of Dermatology in family medicine at Baylor College of Medicine as well as Clinical Instructor of Dermatology at the University of Texas Medical School in Houston. Dr. Teller is being recognized for his efforts and promotion of the NPF mission and key initiatives at the local division with strong contributions and support of the overall NPF goals and objectives.

Outstanding Allied Health, Lakshi Aldredge, MSN, ANP-BCMs. Lakshi Aldredge is a nurse practitioner who has practiced at the Portland VA Medical Center for the past 22 years, the last eight years in the medical Dermatology Service. Aldredge is being recognized for her outstanding achievements in improving psoriatic disease clinical practice and the quality of life of her patients. She is actively involved in the day-to-day clinical care of her patients and is nationally known for her exceptional clinical knowledge and expertise.

Aldredge is the past President of the national Dermatology Nurses' Association (DNA) and is the current Chair of the Nurse Practitioner Society of the DNA. She is on the Advisory board of Dermatology World, is an Associate Editor of Psoriasis Forum, the peer-reviewed journal of the National Psoriasis Foundation, as well as a member of the Editorial Board of the Journal of the Dermatology Nurses' Association.

Over the last 50 years, the National Psoriasis Foundation (NPF) has become the world's leading nonprofit patient advocacy organization fighting for individuals with psoriasis and psoriatic arthritis. NPF leads this fight by driving efforts for a cure and improving the lives of the more than 8 million Americans affected by this chronic disease. To date, NPF has funded more than $15 million in research grants and fellowships, and to commemorate 50 years, NPF plans to raise an additional $2 million for early scientific career research programs in 2017 alone. Each year, NPF strives to support, educate and advocate on behalf of more individuals living with or caring for someone with the disease than ever before. As part of that effort, NPF established the Patient Navigation Center to offer personalized assistance to everyone with psoriasis or psoriatic arthritis. Join our community today and help drive discovery and create community for all living with psoriatic disease.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/national-psoriasis-foundation-2016-medical-professional-awards-winners-300416249.html

SOURCE National Psoriasis Foundation

http://www.psoriasis.org

Original post:
National Psoriasis Foundation 2016 Medical Professional Awards Winners - PR Newswire (press release)

Posted in Psoriasis | Comments Off

Immune Disorders Such as MS, Psoriasis May Be Tied to Dementia … – Helena Independent Record

Posted: at 12:48 am

WEDNESDAY, March 1, 2017 (HealthDay News) -- People with autoimmune diseases -- conditions that cause a person's immune system to turn against the body -- appear to have an increased risk of developing dementia, a new British study suggests.

Researchers found that 18 out of 25 different autoimmune diseases, such as lupus, psoriasis or multiple sclerosis, "showed a statistically significant association with dementia," said study co-author Dr. Michael Goldacre. He's a professor of public health at the University of Oxford.

But Goldacre and other experts stressed that the study didn't prove that autoimmune diseases cause dementia. The research only showed that these conditions are associated with a higher risk of dementia.

Specifically, the study found that people with multiple sclerosis appeared to have nearly double the risk of dementia. Psoriasis was associated with a 29 percent increased risk of dementia. Lupus was linked to a 46 percent increased risk, and rheumatoid arthritis with a 13 percent increased risk. Crohn's disease was associated with a 10 percent increased risk.

"How do [autoimmune diseases] affect the brain? We don't know, although others have suggested that chronic inflammation, possibly autoimmune effects, or possibly both, may have a role in Alzheimer's," Goldacre said.

For this study, the researchers reviewed information from more than 1.8 million people in England. All had been admitted to a hospital with an autoimmune disease between 1998 and 2012.

Compared with people admitted for other causes, patients admitted for treatment of an autoimmune disorder were 20 percent more likely to wind up back at the hospital later with dementia, the researchers found.

However, when researchers broke down their findings by type of dementia, they found that autoimmune diseases only increased the risk of Alzheimer's disease by about 6 percent.

The autoimmune diseases had a much stronger impact on the risk of vascular dementia. The risk of vascular dementia was 28 percent higher in people with autoimmune diseases. People with vascular dementia experience a decline in their thinking skills due to conditions that block or reduce blood flow to the brain, starving brain cells of oxygen and nutrients.

This apparent increased risk for vascular dementia could be caused by the effect of autoimmune diseases on the circulatory system, the researchers said. The study also found that people with an autoimmune disease were 53 percent more likely to be hospitalized for heart disease. Those with an autoimmune disease were also 46 percent more likely to have a stroke.

The link between vascular dementia and autoimmune diseases is "something new," said James Hendrix. He's the director of global science initiatives for the Alzheimer's Association, based in Chicago.

This link could implicate chronic inflammation as a potential cause of progressive dementia, he said.

Hendrix explained that a person with a sprained ankle experiences inflammation and swelling as the immune system responds to their injury. If the inflammation continues for an extended period, that person could wind up with joint damage and arthritis.

"We are starting to think neuron inflammation is similar," Hendrix said.

Both Hendrix and Goldacre noted that the study is observational, so it couldn't prove a direct cause-and-effect link. In addition, Goldacre said the size of the associations they found was small, and should be taken "more as a message for interested researchers than for interested patients."

Dr. Walter Rocca is a professor of epidemiology and neurology with the Mayo Clinic in Rochester, Minn. He said the findings are "important" but may be limited by the fact that the researchers focused solely on people admitted to the hospital with an autoimmune disorder.

"The concern is that many persons affected by an autoimmune disease may never need to be admitted to a hospital, and many persons affected by dementia may not need to be hospitalized," Rocca said.

"This incomplete capture [of information] may cause a distortion of the findings," he added.

Rocca also pointed out that the 25 autoimmune diseases considered in the study are very different from each other. For example, some attack the joints or the endocrine glands, while others -- like multiple sclerosis -- may directly affect the brain.

Findings from the study were published March 1 in the Journal of Epidemiology & Community Health.

Posted in Psoriasis | Comments Off

Doctors reverse teen’s sickle cell disease with innovative gene therapy – Fox News

Posted: at 12:47 am

A French teen who underwent a first-of-its-kind procedure 15 months ago to change his DNA shows no signs of the sickle cell disease he had been suffering from. The procedure, which was performed at Necker Childrens Hospital in Paris, may offer hope to millions of patients who suffer from sickle cell disease, BBC News reported.

Sickle cell disease is a severe hereditary form of anemia, which causes patients to develop abnormal hemoglobin in red blood cells. The botched hemoglobin causes the cells to form a crescent or sickle shape, making it difficult to maneuver throughout the body. Sickle-shaped cells are less flexible, and may get stuck to vessel walls causing a blockage, which can stop blood flow to vital tissues.

Before undergoing the procedure, treatment for the unidentified teen included traveling to the hospital each month for a blood transfusion to dilute the defective blood, BBC News reported. According to the report, the excessive amount of treatment caused severe internal damage, and at age 13 he already needed a hip replacement and had his spleen removed.

In a world first, doctors at Necker Childrens Hospital removed his bone marrow and genetically altered it using a virus to compensate for the defect in his DNA responsible for sickle cell disease, BBC News reported. The results published in the New England Journal of Medicine said he no longer uses medication, and has been making normal blood for the past 15 months.

So far the patient has no sign of the disease, no pain, no hospitalization, Philippe Leboulch, professor of medicine at the University of Paris, told BBC News. He no longer requires a transfusion so we are quite pleased with that.

Doctors said the treatment will have to be repeated in other patients as the teen is the trials first, but that it does show powerful potential.

Ive worked in gene therapy for a long time and we make small steps and know theres years more work, Dr. Deborah Gill, of the gene medicine research group at the University of Oxford, told BBC News. But here you have someone who has received gene therapy and has complete clinical remission thats a huge step forward.

It was not clear how much the procedure would cost, or whether there are plans to expand to other countries.

More:
Doctors reverse teen's sickle cell disease with innovative gene therapy - Fox News

Posted in Gene Medicine | Comments Off

Icahn Names Gene Transfer Pioneer as Portfolio Manager – Genetic Engineering & Biotechnology News

Posted: at 12:47 am

Days after reportedly taking a stake in Bristol-Myers Squibb, Carl C. Icahn signaled an even greater role as an activist investor in biopharma through the hiring of Richard C. Mulligan, Ph.D., as a portfolio manager.

Dr. Mulligan will focus on biotechnology investments for two Icahn limited partnerships, Icahn Partners and Icahn Partners Master Fund, the private investment funds comprising Icahn Enterprises' Investment segment.

"We are very pleased to have Richard join Icahn Capital given the depth and level of experience he brings as we look to enhance our focus on the biotechnology sector," Icahn, the chairman of Icahn Enterprises, said in a statement earlier this week.

Dr. Mulligan is the Mallinckrodt Professor of Genetics, Emeritus at Harvard Medical School (HMS) and visiting scientist at the Koch Institute for Integrative Cancer Research at MIT. He is also a pioneer in the development of new technologies for transferring genes into mammalian cells. A major interest in Dr. Mulligan's laboratory has been the development of genetically engineered animal viruses as gene transfer vectors.

In addition to serving as full Mallinckrodt professor at HMS, he previously served as director of the Harvard Gene Therapy Initiative, a collaboration by basic science and clinical investigators at Harvard University and its affiliated hospitals focused on preclinical and clinical evaluation of novel gene-based therapies for inherited and acquired diseases.

From 2013 to last year, Dr. Mulligan was founding partner and senior managing director of Sarissa Capital Management. Sarissaled by another biopharma-focused activist investor, Alex Dennerspearheaded the successful effort in 2015 to drive Harvey J. Berger, M.D., into retirement from the helm of Ariad Pharmaceuticals, the cancer drug developer that he founded in 1991 and is being acquired by Takeda Pharmaceutical for $5.2 billion.

Dr. Mulligan is a member of Biogens board and has previously served as a director, scientific advisory board member, or officer for numerous public biopharma companies, including Cell Genesys, Cellectis, Enzon, Somatix Therapy, and ImClone. ImClone was acquired by Eli Lilly for $6.5 billion in 2008, 2 years after Icahn acquired a majority of the companys stock.

Dr. Mulligan was also a consultant to Amgen, DuPont, and the Genetics Institute. He previously served on the NIHs Recombinant DNA Advisory Committee, which provides guidance to the agency about experiments involving recombinant DNA, and the FDA Biological Response Modifiers Advisory Committee, which advises the FDA on matters related to cell and gene therapies, including stem cell-based technologies.

He received his B.S. degree from MIT and his Ph.D. from the department of biochemistry at Stanford University School of Medicine, where he studied under Nobel Laureate Paul Berg, Ph.D.

After receiving postdoctoral training at the Center for Cancer Research at MIT with Nobel Laureates David Baltimore, Ph.D., and Phillip Sharp, Ph.D., Dr. Mulligan joined the MIT faculty and was appointed Professor of Molecular Biology and Member of the Whitehead Institute for Biomedical Research before moving to Harvard and Children's Hospital in 1996.

His honors include the MacArthur Foundation "Genius" Prize, the Rhodes Memorial Award of the American Association for Cancer Research, the ASMB-Amgen Award, and the Nagai Foundation International Prize.

Original post:
Icahn Names Gene Transfer Pioneer as Portfolio Manager - Genetic Engineering & Biotechnology News

Posted in Gene Medicine | Comments Off

Invitae CEO wants to democratize genetic testing – MedCity News

Posted: at 12:47 am

MedCity News

Invitae CEO wants to democratize genetic testing
MedCity News
We are in the early days of precision medicine but it is on the back of widespread gene testing that promise of this approach of treating diseases stands. And there are plenty of companies offering some kind of gene testing on the tumor DNA ...

More here:
Invitae CEO wants to democratize genetic testing - MedCity News

Posted in Gene Medicine | Comments Off

Sanford Health, hospital partner on gene sequencing project – Medical Xpress

Posted: at 12:47 am

March 3, 2017

Sanford Health, one of the largest health systems in the country, is partnering with the flagship hospital of the Miami Children's Health System to sequence the genes of nearly 1,000 Latinos and Hispanics in order to better understand the health needs of the populations.

Philanthropist Denny Sanford and Sanford Health have given $7 million to the Nicklaus Children's Hospital initiative in Miami, Florida, to support the research, which uses genetic and genomic information to personalize health carein this case, for children.

Golfing great Jack Nicklaus, for whom the hospital is named, said he recently approached his friend, Denny Sanford, and asked for help with the project.

"When we approached Denny with a plea to assist our important work at Nicklaus Children's Hospital and through our Foundation, he was quick to open his heart and lend a hand," Nicklaus said in a statement.

The sequencing project will make it easier to determine whether a person is predisposed to a certain disease, or how he or she might respond to a particular medicine. The initiative will help build a database of common genomes and identify genetic patterns among Hispanic and Latino populations.

MCHS is South Florida's only health care system exclusively for children and includes the nonprofit Nicklaus Children's Hospital.

Sanford Health, which is the largest employer based in the Dakotas with 28,000 workers, has 45 hospitals and nearly 300 clinics in nine states and four countries. Sanford Health CEO Kelby Krabbenhoft said the partnership will help Sanford diversify its work and research with genomic medicine.

Explore further: Stem cell therapy trial at Sanford first of its kind in US for shoulder injuries

The first FDA-approved clinical trial of its kind in the United States using a person's own fat-derived adult stem cells to treat shoulder injuries is available at Sanford Health.

A 9-day-old baby who suffered a normally fatal stroke was saved after a Sanford Health cerebrovascular neurosurgeon removed the clot by combining mechanical and medicinal therapies. The unique case, completed by Alexander ...

Genetic profiling of cancer tumors provides new avenues for treatment of the disease, according to a study conducted by Sanford Health and recognized by the American Society of Clinical Oncology.

(HealthDay)Sick children from rural areas in the United States have more complex medical problems and cost more to treat than urban or suburban kids, a new hospital study finds.

A drug that blocks neurotransmitters could reduce nausea and vomiting caused by chemotherapy, research co-authored by a Sanford Health physician and published in the New England Journal of Medicine finds.

Snoring can be a normal symptom of a cold or virus in children. But when snoring persists and children have difficulty sleeping, parents should take their children to a doctor to look for signs of more serious conditions.

A condition forcing people to involuntarily mirror movements in opposing limbs has been linked to a common developmental brain disorder.

Common knowledge says that genetic mutations are bad. This is true for most mutations of lipoprotein lipase (LPL), the enzyme in the blood responsible for the breakdown of lipoproteins, which allows tissue to utilize energy ...

A computer method called ZeitZeiger that uses a sample of blood to accurately predict circadian time - the time of day according to a person's body clock - is described in new research published in the open access journal ...

Genetic variants linked to autism spectrum disorders (ASD) may have been positively selected during human evolution because they also contribute to enhanced cognition, a new Yale study suggests.

Australian scientists have discovered the first evidence of genes that cause Macular Telangiectasia type 2 (MacTel), a degenerative eye disease which leads to blindness and is currently incurable and untreatable.

New research has identified sections of DNA associated with altered regulation of gene expression underlying schizophrenia. The implicated loci contribute to schizophrenia risk by affecting alternative splicing, part of the ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

See more here:
Sanford Health, hospital partner on gene sequencing project - Medical Xpress

Posted in Gene Medicine | Comments Off

Epigenetic enzyme found to be lacking in some patients with Crohn’s disease – Medical Xpress

Posted: at 12:47 am

March 3, 2017 High magnification micrograph of Crohn's disease. Biopsy of esophagus. H&E stain. Credit: Nephron/Wikipedia

A Massachusetts General Hospital (MGH) research team has found how a variant in an important epigenetic enzymepreviously associated by population-based genetic studies with Crohn's disease and other immune disordersinterferes with the action of the innate immune system, potentially upsetting the healthy balance between the microbial population of the gastrointestinal tract and the immune response. In their paper published in Science Immunology the team reports findings that SP140an epigenetic reader protein that plays a critical role in determining whether or not target genes are expressedis essential to suppressing inappropriate gene expression in macrophages, innate immune cells that are critical to maintaining intestinal balance.

"More than 400 enzymes write, read or erase the epigenome, and mutations in these enzymes are some of the most prevalent perturbations in cancers, prompting rigorous efforts to identify compounds that could inhibit their function and reset gene expression," says Kate Jeffrey, PhD of the MGH Gastrointestinal Unit and the Center for the Study of Inflammatory Bowel Disease, corresponding author of the Science Immunology report. "Our knowledge of epigenomic enzyme mutations in immune-mediated disease is lagging well behind the cancer field, and our studythe first to examine the function of SP140 in any detailshows how its loss in Crohn's disease triggers intestinal inflammation."

SP140 is predominantly expressed in immune cells, and a variant form of the gene has been associated with Crohn's disease, multiple sclerosis and chronic lymphocytic leukemia. Prior to this study both the normal function of the SP140 protein and how the gene variant affected the protein and caused disease were unknown. In a series of experiments, Jeffrey's team showed that the unaltered form of SP140 is required to maintain the appropriate expression of genes that define the identity and function of macrophages. The immune disorder variantcharacterized by 17 individual sequence changes - resulted in a loss of SP140 protein that compromised the ability of macrophages to respond to microbial signals.

The researchers also showed that reducing SP140 expression in the immune cells of a mouse model of colitis increased intestinal inflammation. In addition, examining intestinal biopsy samples from a group of Crohn's disease patients revealed that those in whom SP140 expression was reduced responded better to anti-TNF (tumor necrosis factor) therapya treatment for inflammatory conditions that is effective in only about half of Crohn's patients - than did patients with typical SP140 levels.

"Finding this correlation between lower intestinal levels of SP140 and a better response to anti-TNF represents a potential precision medicine strategy for tailoring anti-TNF-like therapies to Crohn's patients carrying the variant form of SP140," says Jeffrey, who is an assistant professor of Medicine at Harvard Medical School. "Our study may also lead to better inflammatory bowel disease therapies by highlighting the critical role of epigenetic mechanisms for intestinal health. Although directly targeting SP140 would not be a good option, since its loss is detrimental to intestinal health, leveraging other epigenetic enzyme inhibitors that promote protective innate immune responses in the intestine could be a real therapeutic option"

Additional research is needed to better understand exactly how SP140 normally limits the expression of inappropriate genes and whether this function is limited to macrophages or also occurs in other SP140-expressing immune cells, Jeffrey notes. Her team also hopes to investigate the role of the Crohn's-associated SP140 variant in multiple sclerosis and chronic lymphocytic leukemia, along with identifying other epigenetic enzymes that may be therapeutically targetable in inflammatory bowel disease and other immune-driven disorders.

Explore further: Crohn's disease risk and prognosis determined by different genes, study finds

More information: "Maintenance of macrophage transcriptional programs and intestinal homeostasis by epigenetic reader SP140," Science Immunology, immunology.sciencemag.org/lookup/doi/10.1126/sciimmunol.aag3160

Scientists have revealed for the first time how immature mouse immune cells, called T cells, choose which type of skills they will develop to fight malaria infection. Reported today in Science Immunology, researchers from ...

(HealthDay)An experimental drug may significantly reduce the itching and improve the appearance of moderate to severe eczema, a new, preliminary trial finds.

Scientists have uncovered the physiological mechanics underlying inflammation and obesity by tracking the actions of 'guardian immune cells' in response to changes in diet. They believe their work may herald a new era of ...

The natural life cycle of cells that line the intestine is critical to preserving stable conditions in the gut, according to new research led by a Weill Cornell Medicine investigator. The findings may lead to the development ...

As we head into allergy season, you may feel less likely to grab a hanky and sneeze. That's because new University of Florida research shows a probiotic combination might help reduce hay fever symptoms, if it's taken during ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

See the article here:
Epigenetic enzyme found to be lacking in some patients with Crohn's disease - Medical Xpress

Posted in Gene Medicine | Comments Off

Politically Incorrect – Portsmouth Daily Times

Posted: at 12:46 am

I stand amazed as I watch the nightly news as I see people everywhere that seem to be in such a hurry to scream prejudice and racism these days. It is a daily dose of the worlds newest and most effective tool as those oppressed play the victim card in todays society. They seem to be looking for confrontation at every turn. It seems as if it is a never ending occurrence. It is happening in all kinds of situations. In fact I heard a story about a customer asking a clerk, In what aisle can I find the Polish sausage? The clerk asked, Are you Polish? The woman, who was clearly offended, replied Yes I am. But let me ask you something. If I had asked for Italian sausage, would you ask me if I was Italian? Or if I had asked for German Bratwurst, would you ask me if I was German? Or if I asked for a kosher hot dog would you ask me if I was Jewish? Or if I had asked for a Taco, would you ask if I was Mexican? Or if I asked for some Irish whiskey, would you ask if I was Irish? The clerk rolled his eyes and shook his head and said, No, I probably wouldnt. The woman was clearly upset and said, Well then, because I asked for Polish sausage, why did you ask me if I was Polish? The clerk trying to hold back a grin replied, Because lady youre in Home Depot!

Now folks that story is funny but in todays world it is not politically correct and I would be ostracized for using it. You see today everything is off the table and not politically correct or racist except when someone is attacking Christians, Jesus Christ, or those who hold firmly to the faith that was once delivered. Today it is a national pastime to speak evil of Jesus or the Christian faith. Those that stand for morals and higher standards of conduct are the newest whipping boy for those who seek to take this country into further moral decline.

The world and America would be better if it understood that there is power and true life in the name of Jesus! What happened to the lame man at the temple when Peter told him to arise in the name of Jesus? The man stood up! And not only that, the Scripture says he began to leap and dance and praise God. Later in the temple, Peter testified about the man saying, Look at this man, he stands before you whole and strong in the power of the name of Jesus.

Listen America, in the name of Jesus your bondage can be broken and you can be set free. In the name of Jesus drug addiction can be defeated! In the name of Jesus families can be healed. In the name of Jesus, those who were once broken and downtrodden will be able to stand up and testify of the grace of Christ Jesus in their lives! Now I come to you; yes you! Is the power of Jesus Christ at work in your life today? It can be. Take a leap of faith and live for him! And do it all in the name of Jesus!

Spinnati

http://portsmouth-dailytimes.com/wp-content/uploads/2017/03/web1_Spinnati.jpgSpinnati

Go here to see the original:
Politically Incorrect - Portsmouth Daily Times

Posted in Politically Incorrect | Comments Off

Page 2,004«..10 20..2,0032,0042,005 2,006..2,010 2,020..»

Category Archives: Transhuman News

Does Valeant have the ad dollars to keep Siliq competitive in psoriasis? – FiercePharma

J&J may be late to the psoriasis drug market party, but it’s planning to make a splash with guselkumab – Endpoints News

National Psoriasis Foundation 2016 Medical Professional Awards Winners – PR Newswire (press release)

Immune Disorders Such as MS, Psoriasis May Be Tied to Dementia … – Helena Independent Record

Doctors reverse teen’s sickle cell disease with innovative gene therapy – Fox News

Icahn Names Gene Transfer Pioneer as Portfolio Manager – Genetic Engineering & Biotechnology News

Invitae CEO wants to democratize genetic testing – MedCity News

Sanford Health, hospital partner on gene sequencing project – Medical Xpress

Epigenetic enzyme found to be lacking in some patients with Crohn’s disease – Medical Xpress

Politically Incorrect – Portsmouth Daily Times

The Prometheus League

Breaking News and Updates

Prometheism

Forbidden Fruit

The Evolutionary Perspective

Transtopia Menu

Library Updates

Library Books

Future Euvolution

Lucid Dreams from Childhood

Genetic Revolution

Speciation + Self-Directed Evolution